Home » Stocks » AQST

Aquestive Therapeutics, Inc. (AQST)

Stock Price: $5.53 USD -0.12 (-2.12%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $5.56 +0.03 (0.54%) Jan 27, 6:40 AM
Market Cap 185.92M
Revenue (ttm) 55.12M
Net Income (ttm) -48.05M
Shares Out 33.62M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $5.53
Previous Close $5.65
Change ($) -0.12
Change (%) -2.12%
Day's Open 5.71
Day's Range 5.42 - 5.72
Day's Volume 639,088
52-Week Range 1.54 - 9.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

WARREN, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

GlobeNewsWire - 3 weeks ago

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

Seeking Alpha - 1 month ago

Aquestive Therapeutics are back from the brink, with key advancements in Libervant resubmission and longevity in shareholder value creation. The company entered into a royalty agreement for KY...

GlobeNewsWire - 2 months ago

WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

GlobeNewsWire - 2 months ago

Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million Receives first milestone payment of $10 million, bringing total fourth quarter proceeds t...

GlobeNewsWire - 2 months ago

WARREN, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

Seeking Alpha - 2 months ago

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 2.00% and -3.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

GlobeNewsWire - 2 months ago

WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that addr...

GlobeNewsWire - 2 months ago

WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

Zacks Investment Research - 2 months ago

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

WARREN, N.J., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

Seeking Alpha - 3 months ago

Recent disapproval from FDA regarding Libervant Buccal Film has seen investors react sourly over the last 2 weeks.

24/7 Wall Street - 3 months ago

Aquestive Therapeutics Inc. (NASDAQ: AQST) has announced that it had received a Complete Response Letter (CRL) from the U.S.

GlobeNewsWire - 4 months ago

WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...

Zacks Investment Research - 5 months ago

Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...

Seeking Alpha - 5 months ago

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 5 months ago

WARREN, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ad...

GlobeNewsWire - 6 months ago

WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...

GlobeNewsWire - 6 months ago

WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that a...

GlobeNewsWire - 7 months ago

WARREN, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that ad...

Zacks Investment Research - 7 months ago

Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

WARREN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that add...

Zacks Investment Research - 8 months ago

Is (AQST) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Aquestive Therapeutics.

Zacks Investment Research - 8 months ago

Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 8 months ago

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 9 months ago

Aquestive: Still Looking To Buy In 2020

Zacks Investment Research - 9 months ago

Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for April 14th

Other stocks mentioned: APEN, FATE, MRSN
Seeking Alpha - 10 months ago

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -6.67% and 4.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...

GlobeNewsWire - 11 months ago

WARREN, N.J., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...

GlobeNewsWire - 11 months ago

WARREN, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...

24/7 Wall Street - 1 year ago

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

Other stocks mentioned: ADAP, BNTX, DARE, NKTR, NTGN
24/7 Wall Street - 1 year ago

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares lost nearly a third on Monday after the firm received an update from the U.S. Food and Drug Administration (FDA).

GlobeNewsWire - 1 year ago

WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...

GlobeNewsWire - 1 year ago

WARREN, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated produ...

Seeking Alpha - 1 year ago

Aquestive: Continues To Evolve Into A Promising Long-Term Investment

GlobeNewsWire - 1 year ago

WARREN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq:AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differe...

GlobeNewsWire - 1 year ago

WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differ...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 9th

Other stocks mentioned: AVDL, GRBK, IDN
24/7 Wall Street - 1 year ago

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and ...

GlobeNewsWire - 1 year ago

WARREN, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated prod...

24/7 Wall Street - 1 year ago

Aquestive Therapeutics, Inc. (NASDAQ: AQST) shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval...

About AQST

Aquestive Therapeutics, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemo... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2018
CEO
Keith J. Kendall
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
AQST
Full Company Profile

Financial Performance

In 2019, AQST's revenue was $52.61 million, a decrease of -21.98% compared to the previous year's $67.43 million. Losses were -$66.25 million, 7.93% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 15.00, which is an increase of 171.25% from the latest price.

Price Target
$15.00
(171.25% upside)
Analyst Consensus: Buy